Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12137111 | 0.91 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135163 | 0.88 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135587 | 0.88 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135078 | 0.87 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135046 | 0.85 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135108 | 0.85 | PTK2 (1.00) | PTK2 | |
| Ifebemtinib SCHEMBL29767371 | 0.84 | PTK2 (1.00) | PTK2 | |
| Ifebemtinib SCHEMBL12135026 | 0.84 | PTK2 (1.00) | PTK2 | |
| SCHEMBL12135370 | 0.84 | PTK2 (1.00) | PTK2 | |
| Ifebemtinib SCHEMBL31008531 | 0.84 | PTK2 (0.99) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | PTK2 3591/4885 |
| US-20160362404-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | PTK2 1813/4885 |
| US-20150376141-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | PTK2 1256/4885 |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | PTK2 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.